Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 12, 2001

Primary Completion Date

August 3, 2004

Study Completion Date

August 3, 2004

Conditions
Hemophilia A
Interventions
DRUG

Antihemophilic factor, recombinant, manufactured protein-free

Trial Locations (10)

10029

Mt. Sinai Medical School, Hemophilia Comprehensive Care Center, New York

30322

Children´s Healthcare of Atlanta Blood Bank, Atlanta

45229

Children´s Hospital Medical Center Pharmacy, Hemophilia Treatment Center, Cincinnati

46260

Indiana Hemophilia & Thrombosis Center, Indianapolis

48824

Michigan State University, East Lansing

52242

University of Iowa Hospitals and Clinics, Iowa Regional Hemophilia Center, Department of Pediatrics, Iowa City

90027

Children´s Hospital Los Angeles, Hemophilia Comprehensive Care Center, Division of Pediatric Hematology/Oncology, Los Angeles

02115

Brigham and Women´s Hospital, Hematology Division, Boston

15213-4306

Hemophilia Center of Western Pennsylvania, Pittsburgh

98104-1256

Puget Sound Blood Center, Seattle

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT00157105 - Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery | Biotech Hunter | Biotech Hunter